Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator, known as the PoNS device.
The PoNS device is authorized for sale in Canada as a class II, non-implantable, medical device for the short term treatment of gait deficit due to mild and moderate symptoms from multiple sclerosis, and chronic balance deficit due to mild-to-moderate traumatic brain injury. It is commercially available in Canada via a network of 19 authorized neuro-rehabilitation clinics.
In the U.S., Helius recently received FDA Breakthrough Device Designation for its PoNS device and submitted a request for de novo classification and clearance to the FDA in August. The PoNS device is also under premarket review by the Australian Therapeutic Goods Administration.
Conference presenting at:
Speakers (speaker name, title)
- Dane Andreeff, President and Chief Executive Officer
- Joyce LaViscount, Chief Financial Officer and Chief Operating Officer
- Jonathan Sackier, Chief Medical Officer